Malignant Neoplasms of Lip Oral Cavity and Pharynx Recruiting Phase 2 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0081505 (Malignant Neoplasms of Lip Oral Cavity and Pharynx)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03074513Atezolizumab and Bevacizumab in Treating Patients With Rare Solid TumorsTreatment